Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
Titel:
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
Auteur:
Gadgeel, S. Peters, S. Mok, T. Shaw, A.T. Kim, D.W. Ou, S.I. Pérol, M. Wrona, A. Novello, S. Rosell, R. Zeaiter, A. Liu, T. Nüesch, E. Balas, B. Camidge, D.R.